[1] |
CHEN Yaozhe, ZHAN Yunli, SONG Xingdong, ZHU Manyu, OU Xuemei, LI Chuyun.
48 Cases of Hematological Adverse Reactions Associated with Piperacillin Sodium and Tazobactam Sodium
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 794-798.
|
[2] |
SUN Yinghao, ZANG Shuangyao, YU Wenhui, GUO Shuai, LI Tingting, ZHANG Yi, ZHANG Tingjian, MENG Fanhao.
Effects and Challenges of Pharmacology and Toxicology of Aconitum Diterpenoid Alkaloids
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 601-607.
|
[3] |
XIE Ziyue, WANG Chengxiang, HU Yanpeng, LI Lei, CUI Herong.
Clinical Medications and Safety Analysis of Traditional Chinese Medicine for Post-Infection Cough
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 507-512.
|
[4] |
CHEN Runji, SUN Xiaorui, HUANG Xin, JIANG Zhenzhou, ZHANG Luyong, WANG Xinzhi, DING Jian.
Dynamic Immunophenotyping of NK Cells in Triptolide-Induced Hepatotoxicity
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 517-522.
|
[5] |
WANG Fengxin, LI Lei, HUANG Xurui, ZHAO Yun, LING Ruby, YANG Yang, LIANG Changhao, ZENG Yuntao, ZHENG Yingjun, TANG Yuanchen, LIU Jiatao, WANG Chengxiang, WEN Tiancai, LI Ping.
Efficacy and Safety of Danshen Decoction in Treatment of Coronary Heart Disease
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 575-579.
|
[6] |
ZHANG Yunhui, CHEN Haoyun, ZHONG Luhua, FANG Caifu, HUANG Huanjun, GUO Chenchen, DONG Xinyi, SHI Feng, LIANG Weiting.
159 Cases of Adverse Reactions to Immune Checkpoint Inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 442-446.
|
[7] |
TANG Qianhui, ZHANG Haoran, ZHANG Luyong, JIANG Zhenzhou.
Research Progress in Triptolide-Induced Live Injury
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 121-127.
|
[8] |
WANG Han, WANG Cunxuan, LYU Xuehaiyue, ZHANG Lining, SUO Yusi, GU Zhi'en, WANG Ping, JIN Xuejing.
Chinese Patent Medicines for Preventing Myelosuppression in Adjuvant Treatment of Malignant Tumors: a Systematic Review and Network Meta-Analysis
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 169-176.
|
[9] |
YANG Shengxi, XU Juntong, TU Wenlian.
Research Progress in the Treatment of Advanced Non-Small Cell Lung Cancer with Aumonertinib
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 235-240.
|
[10] |
LU Zhenkai, YANG Dingquan, XIE Zhennian, WANG Lianxin, LI Yuanyuan, WANG Zhifei, CUI Xin, XIE Yanming.
Interpretation and insights from the “Guidelines for Pharmacovigilance of Topical Traditional Chinese Medicines in Clinical Applications”
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1029-1033.
|
[11] |
MENG kangkang, XIA Yukun.
Risks to safety of Ondansetron preparations
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1034-1038.
|
[12] |
LIN Lu, ZHAN Luchuan, LIU Xiaoqi, LIU Ju'e, WANG Laiyou, ZENG Ying, LAI Weihua.
Establish triggers for active monitoring of digoxin adverse events based on the China hospital pharmacovigilance system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1039-1043.
|
[13] |
YAN Yan, LIU Naiyi, QIAO Ling, ZHANG Yi, YANG Chen.
One case of fulminant type 1 diabetes mellitus induced by allopurinol tablets hypersensitivity syndrome
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1068-1070.
|
[14] |
LU Jing, YU Shanshan, TONG Fei, LIN Zhuohui, SONG Luyao.
One case of severe constipation caused by dapagliflozin
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1071-1074.
|
[15] |
ZHANG Jing, ZHANG Kai, YI Zhanmiao.
Efficacy and safety of salvianolic acid preparations for adjuvant therapy on related diseases of coronary heart disease, angina and cerebral infarction: a systematic review
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 910-915.
|